[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1827
1. Erbilgin Y, Sayitoglu M, Hatirnaz O, Dogru O, Akcay A, Tuysuz G, Celkan T, Aydogan G, Salcioglu Z, Timur C, Yuksel-Soycan L, Ure U, Anak S, Agaoglu L, Devecioglu O, Yildiz I, Ozbek U: Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL. Dis Markers; 2010;28(6):353-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL.
  • In this study, the mutation analysis of NOTCH1 and FBXW7 genes was performed in 87 pediatric T-ALLs who were treated on the ALL-BFM protocols.
  • However, NOTCH1 and FBXW7 mutations were not predictive of outcome in the overall cohort of pediatric T-ALLs.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683149.001).
  • [ISSN] 1875-8630
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / NOTCH1 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC3833232
  •  go-up   go-down


2. Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ: DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care; 2005 Aug;9(4):R351-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNase and atelectasis in non-cystic fibrosis pediatric patients.
  • We aimed to evaluate the clinical and radiologic changes in pediatric patients who received DNase for persistent atelectasis that could not be attributed to cardiovascular causes, and who were unresponsive to treatment with inhaled bronchodilators and physiotherapy.
  • METHODS: All non-cystic fibrosis pediatric patients who received nebulised or endotracheally instilled DNase for atelectasis between 1998 and 2002, with and without mechanical ventilation, were analysed in a retrospective descriptive study.
  • CONCLUSION: After treatment with DNase for atelectasis of presumably infectious origin in non-cystic fibrosis pediatric patients, rapid clinical improvement was observed within 2 hours and radiologic improvement was documented within 24 hours in the large majority of children, and increased airway obstruction and ventilation-perfusion mismatch occurred in three children, possibly due to rapid mobilisation of mucus.
  • DNase may be an effective treatment for infectious atelectasis in non-cystic fibrosis pediatric patients.

  • Genetic Alliance. consumer health - BabyFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intensive Care Med. 1996 Jun;22(6):582-4 [8814475.001]
  • [Cites] Eur Respir J. 1996 Apr;9(4):765-9 [8726943.001]
  • [Cites] Pediatr Pulmonol. 1998 Sep;26(3):155-61 [9773909.001]
  • [Cites] Pediatr Pulmonol. 1998 Aug;26(2):147 [9727769.001]
  • [Cites] Crit Care Med. 2000 Feb;28(2):560-2 [10708200.001]
  • [Cites] Pediatr Pulmonol. 2001 May;31(5):377-82 [11340684.001]
  • [Cites] Chest. 2001 Jul;120(1):203-8 [11451839.001]
  • [Cites] Pediatrics. 2001 Aug;108(2):468-70 [11483817.001]
  • [Cites] Eur Respir J. 2001 Oct;18(4):734-7 [11716180.001]
  • [Cites] J Pediatr. 2001 Dec;139(6):813-20 [11743506.001]
  • [Cites] Paediatr Respir Rev. 2000 Sep;1(3):274-8 [12531090.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50393-401 [13679362.001]
  • [Cites] Thorax. 1978 Apr;33(2):235-42 [26989.001]
  • [Cites] Acta Paediatr Scand. 1990 Feb;79(2):219-25 [2321485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188-92 [2251263.001]
  • [Cites] Crit Care Med. 1992 Feb;20(2):193-9 [1737455.001]
  • [Cites] Invest Radiol. 1993 Mar;28(3):214-7 [8486486.001]
  • [Cites] N Engl J Med. 1994 Sep 8;331(10):637-42 [7503821.001]
  • [CommentIn] Crit Care. 2005 Aug;9(4):341-2 [16137380.001]
  • (PMID = 16137347.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.21.1 / DNASE1 protein, human; EC 3.1.21.1 / Deoxyribonuclease I; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC1269442
  •  go-up   go-down


3. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hählen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ: In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood; 2005 Nov 15;106(10):3532-7
Genetic Alliance. consumer health - Pediatric T-cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
  • Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses.
  • Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia.
  • We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor / metabolism. Drug Resistance, Neoplasm. Leukemia, Monocytic, Acute / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Quinolones / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051737.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


Advertisement
4. Hameury F, Mcheik J, Lardy H, Gaudin J, Petit T, Ravasse P, Robert M, Maurage C, Levard G: [Acquired non hypertrophic pyloric stenosis in children]. Arch Pediatr; 2007 Apr;14(4):330-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired non hypertrophic pyloric stenosis in children].
  • [Transliterated title] Sténose acquise non hypertrophique du pylore chez l'enfant.
  • Pediatric non hypertrophic pyloric stenosis (NHPS) are uncommon.
  • MATERIAL AND METHOD: Retrospective review of all cases of NHPS from 3 pediatric surgery services during the period 1984-2002.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187970.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA: WT1 mutations in T-ALL. Blood; 2009 Jul 30;114(5):1038-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular mechanisms involved in disease progression and relapse in T-cell acute lymphoblastic leukemia (T-ALL) are poorly understood.
  • Subsequent analysis showed WT1 mutations in 28 of 211 (13.2%) of pediatric and 10 of 85 (11.7%) of adult T-ALL cases.
  • Survival analysis demonstrated that WT1 mutations do not confer adverse prognosis in pediatric and adult T-ALL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6010-4 [1321431.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Hum Mol Genet. 1993 Mar;2(3):259-64 [8388765.001]
  • [Cites] Blood. 1994 May 15;83(10):2922-30 [8180387.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):351-8 [7795587.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2171-9 [8630376.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Eur J Haematol. 1997 May;58(5):346-9 [9222290.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] Kidney Int. 1998 Jun;53(6):1512-8 [9607183.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):18-25 [15929133.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1212-21 [16956820.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9006-12 [17909001.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] J Exp Med. 2007 Dec 24;204(13):3059-66 [18070937.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):83-93 [18094723.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):380-90 [18421304.001]
  • [Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Genome Biol. 2001;2(8):RESEARCH0032 [11532216.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):416-9 [11878574.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Clin Nephrol. 1985 Dec;24(6):269-78 [3000666.001]
  • [Cites] Genomics. 1989 Nov;5(4):685-93 [2556343.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1257-69 [2163761.001]
  • [Cites] FEBS Lett. 1993 Feb 8;317(1-2):39-43 [8381368.001]
  • (PMID = 19494353.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE15931
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120196-03; United States / NCI NIH HHS / CA / CA114737; United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / MC/ U137686861; United States / NCI NIH HHS / CA / CA02111; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / CA120196-03; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC2721784
  •  go-up   go-down


6. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, Barnes K, Zuurbier L, Meijerink JP, Ferrando AA: NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood; 2008 Aug 1;112(3):733-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterodimerization domain (HD) mutations in NOTCH1 induce ligand-independent activation of the receptor and contribute to the pathogenesis of one-third of human T-cell lymphoblastic leukemias (T-ALLs).
  • Notably, structure-function analysis of leukemia-derived and synthetic JME mutants demonstrated that the aberrant activation of NOTCH1 signaling is dependent on the number of residues introduced in the extracellular juxtamembrane region of the receptor and not on the specific amino acid sequence of these insertions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):166-72 [10712939.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):197-206 [10882062.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] Immunity. 2001 Mar;14(3):253-64 [11290335.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):991-1002 [11581320.001]
  • [Cites] Immunity. 2002 Jun;16(6):869-79 [12121668.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1817-21 [12165504.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Semin Immunol. 2003 Apr;15(2):69-79 [12681943.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):469-79 [15314075.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]
  • [Cites] Development. 1997 Dec;124(23):4759-67 [9428412.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1751-62 [9637676.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8108-12 [9653148.001]
  • [Cites] Science. 1999 Jan 1;283(5398):91-4 [9872749.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):522-5 [10206646.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):314-22 [15665828.001]
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Nat Struct Mol Biol. 2007 Apr;14(4):295-300 [17401372.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [CommentIn] Blood. 2008 Aug 1;112(3):457-8 [18650457.001]
  • (PMID = 18411416.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120196-03; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / CA120196; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Notch1; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC2481531
  •  go-up   go-down


7. Lovisa F, Mussolin L, Corral L, Pillon M, Cazzaniga G, Biondi A, Rosolen A: IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. Lab Invest; 2009 Oct;89(10):1182-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis.
  • We recently reported that minimal residual disease (MRD) and minimal disseminated disease (MDD), assessed by long-distance PCR (LD-PCR) for t(8;14), are negative prognostic factors in mature B-cell acute lymphoblastic leukemia (B-ALL) and in Burkitt's lymphoma (BL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, B-Lymphocyte, Light Chain. Immunoglobulin Heavy Chains / genetics. Immunoglobulin kappa-Chains / genetics. Leukemia, B-Cell / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668242.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


8. Van Vlierberghe P, Homminga I, Zuurbier L, Gladdines-Buijs J, van Wering ER, Horstmann M, Beverloo HB, Pieters R, Meijerink JP: Cooperative genetic defects in TLX3 rearranged pediatric T-ALL. Leukemia; 2008 Apr;22(4):762-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cooperative genetic defects in TLX3 rearranged pediatric T-ALL.
  • T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder, in which multiple genetic abnormalities cooperate in the malignant transformation of thymocytes.
  • About 20% of pediatric T-ALL cases are characterized by TLX3 expression due to a cryptic translocation t(5;14)(q35;q32).
  • [MeSH-major] Chromosome Aberrations. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Sequence Deletion

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185524.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / TLX3 protein, human; 0 / WT1 Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


9. Bourassa-Moreau E, Labelle H, Mac-Thiong JM: Radiological and clinical outcome of non surgical management for pediatric high grade spondylolisthesis. Stud Health Technol Inform; 2010;158:177-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological and clinical outcome of non surgical management for pediatric high grade spondylolisthesis.
  • OBJECTIVE: To describe and compare the quality of life of patients with pediatric high-grade spondylolisthesis managed non-operatively and operatively.
  • SUMMARY OF BACKGROUND DATA: Some authors consider pediatric high-grade spondylolisthesis as an absolute indication for surgery, regardless of symptoms while others sometimes recommend observation in asymptomatic patients.
  • Very little is known about the indications and outcome of non-operatively managed high-grade spondylolisthesis.
  • METHODS: A prospective database comprising all the spondylolisthesis cases from a single pediatric institution was reviewed in order to identify all cases of high grade spondylolisthesis.
  • Non-operatively treated patients were identified and compared to surgically treated patients at baseline and at last follow-up.
  • RESULTS: 34 spondylolisthesis were identified as high grade and 5 of them were non-operatively treated.
  • Quality of life questionnaires showed less impairment in the non-operative group when compared to the surgical group preoperatively.
  • There was no worsening of quality of life observed in non-operative patients during follow-up.
  • CONCLUSION: The quality of life after surgical treatment of high grade spondylolisthesis is similar to that of patients with high grade spondylolisthesis and mild symptoms undergoing non-operative treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20543420.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia; 2008 Jan;22(1):124-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences.
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages.
  • We extensively studied 72 pediatric T-ALL cases for genetic abnormalities and expression of transcription factors, NOTCH1 mutations and expression of specific CD markers.
  • [MeSH-major] Gene Rearrangement / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Recurrence, Local / genetics. Receptor, Notch1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928886.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TLX3 protein, human; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


11. Fass J, Tichy EH, Kraus EW, Herrick JL, Ehsan A, Peterson J, Grimwood RE: Cutaneous tumors as the initial presentation of non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy in an adolescent boy. Pediatr Dermatol; 2005 Jan-Feb;22(1):19-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous tumors as the initial presentation of non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy in an adolescent boy.
  • Based on this information, the patient was diagnosed with the recently described, rare non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660891.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  •  go-up   go-down


12. Sandler ES, Homans A, Mandell L, Amylon M, Wall DA, Devidas M, Buchanan GR, Lipton JM, Billett AL: Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. J Pediatr Hematol Oncol; 2006 Apr;28(4):210-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study.
  • BACKGROUND: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis.
  • PROCEDURE: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin.
  • [MeSH-major] Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation


13. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • Mean length of survivors 4 year (range 4-140 month) and mean length for non-survivors 1 year (range 0.1-40 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. da Costa Moraes CA, Trompieri NM, Cavalcante Felix FH: Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital. J Pediatr Hematol Oncol; 2008 May;30(5):387-90
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital.
  • Acute promyelocytic leukemia (APL) is an uncommon form of pediatric acute nonlymphocytic leukemia.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Brazil. Female. Hospitals, Pediatric. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458575.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


16. Hori T, Suzuki N, Mizue N, Hatakeyama N, Takamuro M, Tsutsumi H: Relapse of T-cell all after stem cell transplant presenting as hypertrophic cardiomyopathy: the value of non-invasive diagnostic imaging in detecting cardiac leukemia. Pediatr Blood Cancer; 2006 Jan;46(1):108-11
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of T-cell all after stem cell transplant presenting as hypertrophic cardiomyopathy: the value of non-invasive diagnostic imaging in detecting cardiac leukemia.
  • We describe a 14-year-old female with acute lymphoblastic leukemia (ALL) with a mediastinal mass at diagnosis who developed hypertrophic cardiomyopathy (HC) after stem cell transplantation (SCT).
  • However, isolated cardiac relapse was finally diagnosed by several non-invasive imaging techniques.
  • [MeSH-major] Cardiomyopathy, Hypertrophic / etiology. Diagnostic Imaging. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Myocardium / pathology

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078227.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Biswas A, Tiwari AK, Ranjan R, Meena A, Akhter MS, Yadav BK, Behari M, Saxena R: Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian-Indian patients. Ann Hematol; 2009 May;88(5):473-8
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian-Indian patients.
  • Since the underlying etiology in pediatric strokes is different than adults, looking for genetic causes would be the logical thing to do in the pediatric stroke population.
  • MTHFR 677 C>T showed the strongest association and therefore may have a strong predisposing role for pediatric strokes.
  • Polymorphisms in HPA-I and MTHFR may have important predisposing roles in the development of pediatric stroke.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836720.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Integrin beta3; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 3.4.17.20 / Carboxypeptidase B2
  •  go-up   go-down


18. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, Reznickova L, Valova T, Zdrahalova K, Hrusak O, Jabali Y, Schrappe M, Conter V, Izraeli S, Li CK, Stark B, Stary J, Trka J: Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia; 2008 May;22(5):989-97

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
  • MRD negativity at day 33 was associated with an age of 1-5 years, WBC<20,000 microl(-1), non-T immunophenotype, good prednisone response and non-M3 morphology at day 15.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305563.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, Li W, McKenna K, Liu XS, Feng B, Neuberg D, Silverman L, DeAngelo DJ, Kutok JL, Rothstein R, DePinho RA, Chin L, Lee C, Look AT: Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med; 2007 Dec 24;204(13):3059-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have demonstrated that the MYB oncogene is frequently duplicated in human T cell acute lymphoblastic leukemia (T-ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5323-8 [11034064.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):370-9 [11988762.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):160-5 [12185367.001]
  • [Cites] EMBO J. 2003 Sep 1;22(17):4478-88 [12941699.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):721-9 [15195090.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4744-8 [15256441.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14853-8 [15466706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Aug;79(15):4714-7 [6289315.001]
  • [Cites] Cell. 1982 Dec;31(2 Pt 1):453-63 [6297766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jul;81(14):4534-8 [6589609.001]
  • [Cites] Mol Cell Biol. 1988 Feb;8(2):884-92 [2832742.001]
  • [Cites] Cancer Lett. 1990 Jun 30;52(1):57-62 [2354420.001]
  • [Cites] J Exp Med. 1991 Oct 1;174(4):867-73 [1680958.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2519-23 [1461655.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1812-7 [7475267.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2205-12 [8950988.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2390-5 [9482895.001]
  • [Cites] Am J Hum Genet. 1999 Jan;64(1):300-2 [9915971.001]
  • [Cites] Genes Dev. 1999 May 1;13(9):1073-8 [10323859.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Mol Genet Metab. 1999 Jul;67(3):183-93 [10381326.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2331-42 [16166372.001]
  • [Cites] Blood. 2006 Aug 1;108(3):896-903 [16597594.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1065-74 [16815104.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] EMBO J. 2000 Nov 15;19(22):6112-20 [11080157.001]
  • (PMID = 18070937.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE7615
  • [Grant] United States / NCI NIH HHS / CA / P01 CA109901; United States / NIGMS NIH HHS / GM / R37 GM050237; United States / NCI NIH HHS / CA / CA11560; United States / NIGMS NIH HHS / GM / GM067055; United States / NIGMS NIH HHS / GM / R01 GM067055; United States / NIGMS NIH HHS / GM / R01 GM050237; United States / NCI NIH HHS / CA / R01 CA111560; United States / NCI NIH HHS / CA / R21 CA115853; United States / NIGMS NIH HHS / GM / GM050237; United States / NCI NIH HHS / CA / CA115853; United States / NCI NIH HHS / CA / CA68484-11; United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / CA109901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myb
  • [Other-IDs] NLM/ PMC2150982
  •  go-up   go-down


20. Huang L, Lequin M, Pieters R, van den Heuvel-Eibrink MM: The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma. Pediatr Blood Cancer; 2007 Apr;48(4):468-72
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The aim of this study was to evaluate the value of follow-up investigations of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), including cerebrospinal fluid (CSF) examination, bone marrow (BM) aspiration, peripheral blood (PB) count, serum lactate dehydrogenase (LDH) and chest X-rays in patients with an initial mediastinal enlargement.
  • PROCEDURE: We reviewed clinical records of all T-ALL patients from 1987 to 2002 and all T-NHL patients from 1977 to 2002, seen at a single institution.
  • All T-ALL and T-NHL patients with a mediastinal relapse were symptomatic.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis


21. Gualco G, Klumb CE, Barber GN, Weiss LM, Bacchi CE: Pediatric lymphomas in Brazil. Clinics (Sao Paulo); 2010;65(12):1267-77
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric lymphomas in Brazil.
  • OBJECTIVE: This study provides the clinical pathological characteristics of 1301 cases of pediatric/adolescent lymphomas in patients from different geographic regions of Brazil.
  • METHODS: A retrospective analyses of diagnosed pediatric lymphoma cases in a 10-year period was performed.
  • We believe that it represents the largest series of pediatric lymphomas presented from Brazil.
  • RESULTS: Non-Hodgkin lymphomas represented 68% of the cases, including those of precursor (36%) and mature (64%) cell origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2009 Jul;132(1):28-33 [19864230.001]
  • [Cites] Semin Oncol. 2009 Oct;36(5):381-418 [19835736.001]
  • [Cites] Cancer Epidemiol. 2009 Dec;33(6):403-5 [19833572.001]
  • [Cites] Int J Cancer. 2010 Feb 1;126(3):715-20 [19642142.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 May;24(4):269-73 [11972094.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):25-30 [12109852.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:147-52 [12401681.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):57-66 [12802810.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2622-31 [14642924.001]
  • [Cites] Clin Lymphoma. 2003 Dec;4(3):161-8 [14715098.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1687-9 [15370226.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):407-13 [15455481.001]
  • [Cites] Cancer. 2000 May 15;88(10):2378-86 [10820362.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):20-7 [10881003.001]
  • [Cites] Cad Saude Publica. 2002 Jan-Feb;18(1):33-44 [11910422.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Cancer. 1978 Aug;42(2):787-92 [687386.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):77-83 [7505777.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1993 Oct;17(3):337-8 [8271140.001]
  • [Cites] Med Pediatr Oncol. 1996 Feb;26(2):90-4 [8531859.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):243-8 [8972760.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):92-8 [8980374.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):248-54 [9078320.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):519-25 [9324338.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):465-9 [15621841.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):109-15 [15894921.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Sao Paulo Med J. 2005 May 2;123(3):134-6 [16021277.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):616-22 [16127683.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Curr Oncol Rep. 2006 Sep;8(5):387-94 [16901400.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):568-74 [17006262.001]
  • [Cites] Hum Hered. 2006;62(4):190-5 [17106202.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):139-44 [16642484.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):179-85 [17526010.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):761-8 [17760808.001]
  • [Cites] Curr Oncol Rep. 2007 Nov;9(6):459-65 [17991353.001]
  • [Cites] J Pediatr (Rio J). 2007 Nov-Dec;83(6):547-54 [18074060.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Apr;30(4):285-91 [18391697.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):196-201 [18227720.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):910-6 [18464110.001]
  • [Cites] Pediatrics. 2008 Jun;121(6):e1470-7 [18519450.001]
  • [Cites] Hematology. 2008 Apr;13(2):114-8 [18616879.001]
  • [Cites] Pediatr Blood Cancer. 2008 Sep;51(3):369-74 [18493992.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Am J Clin Pathol. 2008 Dec;130(6):946-56 [19019773.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Am J Surg Pathol. 2009 Dec;33(12):1815-22 [19816150.001]
  • (PMID = 21340214.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI073961
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC3020336
  •  go-up   go-down


22. Dawidowska M, Jółkowska J, Szczepański T, Derwich K, Wachowiak J, Witt M: Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience. Arch Immunol Ther Exp (Warsz); 2008 Nov-Dec;56(6):409-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.
  • INTRODUCTION: Minimal residual disease (MRD), detected based on immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements as markers of residual leukemic cells, is currently the most reliable prognostic factor in acute lymphoblastic leukemia (ALL).
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Child, Preschool. Europe. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Infant. Male. Poland. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Receptors, Antigen, T-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Sep;15(9):1485-7 [11516112.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Leukemia. 2002 May;16(5):928-36 [11986956.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1372-80 [12094263.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1573-82 [12886245.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1834-44 [12970784.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):267-73 [14687622.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4602-9 [15010366.001]
  • [Cites] Eur J Immunol. 1991 May;21(5):1311-4 [1903708.001]
  • [Cites] J Immunol. 1992 Jul 15;149(2):511-6 [1624797.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1892-902 [8142656.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1139-45 [8035605.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):685-93 [8826893.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1719-23 [8892674.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2192-9 [9447840.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2200-7 [9447841.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1971-80 [15470492.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):795-800 [16386788.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1119-25 [16476479.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1065-6 [16513167.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leuk Res. 2000 Jul;24(7):575-82 [10867131.001]
  • [Cites] Blood. 2000 Jul 1;96(1):63-70 [10891431.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2254-61 [10979974.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1415-23 [11516102.001]
  • (PMID = 19043668.001).
  • [ISSN] 1661-4917
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ PMC2805919
  •  go-up   go-down


23. Schraders M, van Reijmersdal SV, Kamping EJ, van Krieken JH, van Kessel AG, Groenen PJ, Hoogerbrugge PM, Kuiper RP: High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage. Cancer Genet Cytogenet; 2009 May;191(1):27-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage.
  • Lymphoblastic lymphoma (LBL) is one of the most frequent occurring pediatric non-Hodgkin lymphomas.
  • In the WHO classification scheme, pediatric LBL is considered to be the same disease entity as pediatric acute lymphoblastic leukemia (ALL).
  • However, it is unclear whether the genetic basis of pediatric LBL development is similar to that of pediatric ALL.
  • We performed genome-wide analyses of copy number aberrations in 12 T-LBL and 7 precursor B-cell LBL pediatric cases using high-resolution SNP-based array CGH.
  • Taken together, our data suggest that pediatric LBL and ALL exhibit similar genomic abnormalities within confined immunophenotypic and cytogenetic subgroups, but that the representations of these subgroups differs between the two entities.
  • [MeSH-major] B-Lymphocytes / pathology. Cell Lineage. Gene Expression Profiling. Genome, Human / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Cell Cycle. Child. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 9 / genetics. Gene Duplication. Gene Expression Regulation, Leukemic. Humans. Polyploidy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. T-Lymphocytes / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389505.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT: Activating Notch1 mutations in mouse models of T-ALL. Blood; 2006 Jan 15;107(2):781-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutations in NOTCH1.
  • We sequenced the heterodimerization domain and the PEST domain of Notch1 in our mouse model of TAL1-induced leukemia and found that 74% of the tumors harbor activating mutations in Notch1.
  • [MeSH-major] Disease Models, Animal. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma / genetics. Mutation / genetics. Receptor, Notch1 / genetics. Thymus Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3831-42 [10805726.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3023-31 [16407836.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] J Virol. 2000 Oct;74(20):9786-91 [11000255.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Science. 2002 May 3;296(5569):922-7 [11934988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8173-8 [12034884.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cell. 2003 Aug 8;114(3):359-70 [12914700.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2593-6 [12816868.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1992 Mar 6;68(5):855-67 [1547487.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5160-6 [8895560.001]
  • [Cites] Oncogene. 1998 Jan 29;16(4):517-22 [9484841.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 16166587.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / H2AX protein, mouse; 0 / Histones; 0 / NOTCH1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Rag2 protein, mouse; 0 / Receptor, Notch1; 0 / Tal1 protein, mouse; 0 / Tumor Suppressor Protein p53; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.- / Endopeptidases; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / BACE1 protein, human; EC 3.4.23.46 / Bace1 protein, mouse
  • [Other-IDs] NLM/ PMC1895623
  •  go-up   go-down


25. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • PROCEDURE: XIAP protein and mRNA expression were determined in leukemic blasts of 51 childhood ALL patients and normal bone marrow mononuclear cells.
  • RESULTS: XIAP protein but not mRNA expression was found to be highly increased in childhood ALL compared to control bone marrow mononuclear cells (MNC) (median: 3.5 vs. 0.14 ng/10(5) MNC, P < 0.0001) indicating a post-transcriptional regulation of XIAP expression.
  • CONCLUSION: In childhood ALL compared to control bone marrow, the expression of the apoptosis inhibitor XIAP is highly increased by post-transcriptional regulation.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582956.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


26. Kolenova A, Hikkel I, Ilencikova D, Hikkelova M, Sejnova D, Kaiserova E, Cizmar A, Puskacova J, Bubanska E, Oravkinova I, Gencik M: Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience. Neoplasma; 2010;57(6):552-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
  • Acute lymphoblastic leukemia is the most common form of cancer in children.
  • An intense effort has been made to develop methods to determine the degree of minimal residual leukemia cells present in patients considered to be in morphological remission.
  • A total of 40 patients with BCP-ALL ( B cell precursor ALL) and 4 patients with T ALL were analyzed for Ig/TCR rearrangement.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845994.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


27. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D: Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica; 2007 Aug;92(8):1043-50
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
  • To date, however, there is no information available on the prognostic role of survivin in pediatric precursor B-cell acute lymphocytic leukemia (BCP-ALL), the most frequent malignancy in childhood.
  • DESIGN AND METHODS: In a retrospective study including 66 pediatric patients we analyzed the impact of survivin protein levels on outcome in BCP-ALL.
  • RESULTS: Survivin overexpression, with an up to ten-fold increase of the normal level, was detected in 65% of the leukemic samples in contrast to negligible expression in non-malignant hematopoietic cells.
  • [MeSH-major] Inhibitor of Apoptosis Proteins / analysis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640858.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


28. Al-Khabori M, Minden MD, Yee KW, Gupta V, Schimmer AD, Schuh AC, Xu W, Brandwein JM: Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. Leuk Lymphoma; 2010 Jan;51(1):61-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.
  • All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed.
  • From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n = 32).
  • The two groups (DFCI and non-DFCI) had comparable baseline characteristics.
  • Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups.
  • On multivariate analysis, the treatment group (DFCI vs. non-DFCI) was the major prognostic factor influencing both RFS and OS.
  • The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality


29. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, Saito N, Yang SM, Iwamoto C, Okamura J, Liu KY, Huang XJ, Lu DP, Shultz LD, Harada M, Ishikawa F: CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia; 2008 Jun;22(6):1207-13
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
  • In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction.
  • To understand the origin of malignant cells in primary human B-precursor acute lymphocytic leukemia (B-ALL), we established a novel in vivo xenotransplantation model.
  • Purified CD34+CD38+CD19+, CD34+CD38-CD19+ and CD34+CD38-CD19- bone marrow (BM) or peripheral blood (PB) cells from three pediatric B-ALL patients were intravenously injected into sublethally irradiated newborn NOD/SCID/IL2rgamma(null) mice.
  • The identification of CD34+CD38+CD19+ self-renewing B-ALL cells proposes a hierarchy of leukemia-initiating cells (LICs) distinct from that of AML.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Hematopoietic Stem Cells / pathology. Neoplastic Stem Cells / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418410.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


30. Sangkhathat S, Kusafuka T, Nara K, Yoneda A, Fukuzawa M: Non-random p53 mutations in pediatric undifferentiated (embryonal) sarcoma of the liver. Hepatol Res; 2006 Aug;35(4):229-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-random p53 mutations in pediatric undifferentiated (embryonal) sarcoma of the liver.
  • Previously, we found a p53 mutation in a case of pediatric USL.
  • In this study, we analyzed in three cases of pediatric USL and two cases of MH by using PCR-SSCP and direct sequencing technique.
  • In summary, this study provided a novel data suggesting that mutations of p53 in pediatric USL are not random genetic events and highly possible to be involved in its tumorigenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757210.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


31. Eidlitz-Markus T, Mukamel M, Haimi-Cohen Y, Amir J, Zeharia A: Breast asymmetry during adolescence: physiologic and non-physiologic causes. Isr Med Assoc J; 2010 Apr;12(4):203-6
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast asymmetry during adolescence: physiologic and non-physiologic causes.
  • BACKGROUND: Pathologic breast conditions are rare in childhood and adolescence.
  • The spectrum of breast disease in the pediatric age group is different from that in adults, and most lesions are benign.
  • METHODS: The files of patients with a diagnosis of breast asymmetry referred to a tertiary pediatric center from 1990 to 2007 were reviewed for history and findings on physical examination with or without imaging, treatment and outcome.
  • In most cases a precise medical history and physical examination can differentiate between physiologic and non-physiologic causes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20803877.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


32. Starkova J, Zamostna B, Mejstrikova E, Krejci R, Drabkin HA, Trka J: HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL. Pediatr Blood Cancer; 2010 Dec 1;55(6):1072-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL.
  • However, HOX expression patterns in leukemia cells compared to normal lymphoid progenitors have not been systematically studied in acute lymphoblastic leukemia (ALL) subtypes.
  • PROCEDURE: The RNA expression levels of HOXA, HOXB, and CDX1/2 genes were analyzed by qRT-PCR in a cohort of 61 diagnostic pediatric ALL samples and FACS-sorted subpopulations of normal lymphoid progenitors.
  • HOXA7 gene was low expressed at the RNA level in patients with hyperdiploid leukemia, whereas HOXB7 and CDX2 genes were low expressed in TEL/AML1-positive and BCR/ABL-positive cases, respectively.
  • In contrast to previous findings in acute myeloid leukemia, high HOXA RNA expression was associated with an excellent prognosis in Cox's regression model (P = 0.03).
  • CONCLUSIONS: HOX gene RNA expression cannot discriminate leukemia subgroups or relative maturity of leukemic cells.
  • [MeSH-major] Gene Expression Regulation, Leukemic / physiology. Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672366.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX1 protein, human; 0 / CDX2 protein, human; 0 / HOXB2 protein, human; 0 / HOXB4 protein, human; 0 / Homeodomain Proteins; 0 / HoxB3 protein, human; 0 / Transcription Factors; 157907-48-7 / HoxA protein
  •  go-up   go-down


33. Cecchetto G, Alaggio R, Dall'Igna P, Bisogno G, Ferrari A, Gigante C, Casanova M, Sotti G, Zanetti I, Carli M: Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer; 2005 Nov 1;104(9):2006-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies.
  • BACKGROUND: Treatment of initially unresectable nonrhabdo soft tissue sarcomas (NRSTS) in pediatric age is debated, due to their different chemosensitivity.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16161038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS: Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 May 1;12(9):2662-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.
  • To determine if Mer expression is ectopic in T-cell acute lymphoblastic leukemia (ALL) and potentially important in leukemogenesis, we analyzed Mer expression in normal human thymocytes and lymphocytes and in pediatric ALL patient samples.
  • CONCLUSIONS: Transforming Mer signals may contribute to T-cell leukemogenesis, and abnormal Mer expression may be a novel therapeutic target in pediatric ALL therapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675557.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / CA 68346; United States / NCI NIH HHS / CA / P30 CA46934; United States / NCI NIH HHS / CA / T32CA8608604
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; EC 2.7.10.1 / MERTK protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


35. Akiyama M, Yamada O, Agawa M, Yuza Y, Yanagisawa T, Eto Y, Yamada H: Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia. J Pediatr Hematol Oncol; 2008 Apr;30(4):313-6
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia.
  • Although glucocorticoid is essential in the treatment of pediatric acute lymphoblastic leukemia (ALL), their precise mechanisms of action remain unclear.
  • We used DNA microarray to evaluate prednisolone-regulated genes in pre-B-ALL cells from 2 pediatric patients.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Lymphoma, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391702.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


36. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, Koehler R, Tolle G, Bandapalli OR, Breit S, Muckenthaler MU, Kulozik AE: The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia; 2010 Dec;24(12):2005-13
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Precursor T-cell acute lymphoblastic leukemia (T-ALL) remains an important challenge in pediatric oncology.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Steroids.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Apr 1;103(7):2771-8 [14684422.001]
  • [Cites] Science. 2004 Feb 27;303(5662):1374-8 [14739463.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):231-43 [15238145.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Blood. 1989 Oct;74(5):1762-7 [2676018.001]
  • [Cites] Blood. 1991 Jan 15;77(2):331-9 [1824678.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1898-909 [9731046.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Blood. 2010 Apr 22;115(16):3206-14 [20154213.001]
  • [Cites] Leukemia. 2010 Dec;24(12):2014-22 [20861909.001]
  • [Cites] EMBO J. 2004 May 19;23(10):2116-25 [15103331.001]
  • [Cites] Ann Hematol. 1999 Apr;78(4):157-62 [10348146.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:118-45 [15561680.001]
  • [Cites] Nature. 2004 Dec 9;432(7018):775-9 [15592418.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):379-91 [16054087.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Mol Cell. 2007 Apr 13;26(1):131-43 [17434132.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] Science. 2008 Sep 12;321(5895):1499-502 [18787170.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Br J Haematol. 2009 Apr;145(2):198-206 [19245433.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):1000-4 [19536265.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Blood. 2009 Jul 16;114(3):647-50 [19458356.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1053-62 [19406988.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1417-25 [19340001.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4352-6 [19635999.001]
  • [Cites] Haematologica. 2009 Oct;94(10):1383-90 [19794083.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7403-15 [11585921.001]
  • [Cites] Science. 2001 Oct 5;294(5540):173-7 [11533444.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] J Neurochem. 2002 Sep;82(6):1540-8 [12354302.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):569-70; author reply 570-1 [14752084.001]
  • [CommentIn] Leukemia. 2010 Dec;24(12):2003-4 [21157484.001]
  • (PMID = 20944675.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC3035973
  •  go-up   go-down


37. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, Burkhardt B, Gesk S, Krams M, Reiter A, Siebert R, Klapper W: Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica; 2010 Feb;95(2):253-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials.
  • Background Pediatric follicular lymphoma has recently been recognized as a novel variant of follicular lymphoma in the World Health Organization classification of lymphomas.
  • DESIGN AND METHODS: We analyzed 25 cases of pediatric follicular lymphoma (patients aged <or=18 years) by morphology, immunohistochemistry and interphase fluorescence in situ hybridization.
  • All patients analyzed were treated within Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials, and the cohort was representative of the German population.
  • RESULTS: The genetic hallmark of adult follicular lymphoma, t(14;18)(q32;q21), was not detectable in any of the pediatric cases, although BCL2 protein was expressed in 55% of the latter cases.
  • Patients with pediatric follicular lymphoma had long event-free survival and, in contrast to adult follicular lymphoma, the clinical course was not dominated by relapses.
  • Conclusions Our data suggest that pediatric follicular lymphoma is a disease that differs from its adult counterpart both genetically and clinically.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):166-78 [18492111.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Cancer. 1979 Apr;43(4):1216-24 [376087.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Mod Pathol. 1990 May;3(3):308-13 [2194214.001]
  • [Cites] Leukemia. 1992 Aug;6(8):761-5 [1640726.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1374-81 [18509088.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5165-9 [18838711.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):958-63 [19030176.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 19679882.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ PMC2817028
  •  go-up   go-down


38. Bilić E, Femenić R, Konja J, Simat M, Dubravcić K, Batinić D, Ries S, Rajić L: CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol; 2010 Mar;34(1):171-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
  • Lymphomas represent the third most common group of cancers in childhood and adolescence, mature B non Hodgkin's lymphoma (B-NHL) accounting for up to 60% of newly diagnosed patients.
  • The effect of rituximab in pediatric population is still not well enough investigated.
  • The number of our patients is too small and the follow-up of a larger group of patients will help in defining the role of rituximab in the treatment of childhood B-NHL.


39. Karremann M, Rausche U, Fleischhack G, Nathrath M, Pietsch T, Kramm CM, Wolff JE: Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neurooncol; 2010 Apr;97(2):257-65
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and epidemiological characteristics of pediatric gliosarcomas.
  • We studied the clinical relevance of this histological glioblastoma subentity within the pediatric population.
  • We obtained patient data from the German HIT-GBM database, which contains clinical data for more than 600 pediatric patients with centrally reviewed high-grade gliomas.
  • In the whole series of 23 pediatric GS patients, including previously reported cases, the male-to-female-ratio was 1.2:1.
  • GS was found in all pediatric age groups with a median age of 11 years, but there was an unexpectedly high accumulation in infants (6 of 23 <3 years of age, 26%).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806321.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M: NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood; 2008 Jan 1;111(1):376-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NOTCH1 mutations are common in T-lineage acute lymphoblastic leukemia (T-ALL).
  • Twin studies and retrospective screening of neonatal blood spots provide evidence that fusion genes and other chromosomal abnormalities associated with pediatric leukemias can originate prenatally.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17901244.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


41. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


42. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T, Konishi N: Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol; 2007 Apr;9(2):113-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of pediatric astrocytic tumors.
  • Astrocytomas are the most common pediatric brain tumors, accounting for 7%-8% of all childhood cancers.
  • Relatively few studies have been performed on their molecular properties; therefore, classification of pediatric astrocytic tumors into genetic subtypes similar to that of adult tumors remains to be defined.
  • Here, we report an extensive characterization of 44 pediatric astrocytomas--16 diffuse astrocytomas (WHO grade II), 10 anaplastic astrocytomas (WHO grade III), and 18 glioblastomas (WHO grade IV)--in terms of genetic alterations frequently observed in adult astrocytomas.
  • Loss of heterozygosity (LOH) on 1p/19q and 10p/10q was less common in pediatric astrocytic tumors than in those seen in adults, but the frequency of LOH on 22q was comparable, occurring in 44% of diffuse astrocytomas, 40% of anaplastic astrocytomas, and 61% of glioblastomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Acta Neuropathol. 2005 Oct;110(4):402-10 [16155764.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 1990 May 15;50(10):2987-90 [2334901.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3229-36 [8490859.001]
  • [Cites] Brain Pathol. 1993 Jan;3(1):19-26 [8269081.001]
  • [Cites] Oncogene. 1994 Mar;9(3):949-54 [8108140.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):967-72; discussion 972-3 [8084407.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(2-3):100-12 [8978759.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):559-64 [9650746.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 [9690672.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4085-90 [10632344.001]
  • (PMID = 17327574.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1871665
  •  go-up   go-down


43. Verstegen RH, Kusters MA, Gemen EF, DE Vries E: Down syndrome B-lymphocyte subpopulations, intrinsic defect or decreased T-lymphocyte help. Pediatr Res; 2010 May;67(5):563-9
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DS serum immunoglobulin levels were compared with 962 non-DS children with recurrent infections.
  • Immunoglobulin levels in DS are abnormal-as has been described before-and different from non-DS children with recurrent infections.

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098344.001).
  • [ISSN] 1530-0447
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


44. Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, Park S, Park BB, Ko YH, Kim K, Koo HH, Kim WS: Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group. Clin Lymphoma Myeloma; 2007 Nov;7(9):580-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group.
  • PURPOSE: The aim of this study is to define distinctive clinicopathologic features of malignant lymphoma in pediatric and young adult patients, particularly in Korea.
  • PATIENTS AND METHODS: From May 1993 to November 2005, 294 pediatric and young adult patients (age range, 0-31 years) with malignant lymphoma were analyzed in this study at Samsung Medical Center.
  • Among patients with non-Hodgkin lymphoma (NHL), T/natural killer cell immunophenotype is more common in the present younger age group than the all-ages group (45.5% vs. 25%; P = .001) and Western younger age group (45.5% vs. 13.3%; P = .001).
  • Lymphoblastic lymphoma and T-anaplastic large-cell lymphoma included relatively higher proportions in the younger age group.
  • CONCLUSION: The incidence of Hodgkin disease and T-cell NHL is relatively higher in pediatric and young-adult population group than the all-ages group.
  • However, treatment outcome of the younger age group, excluding lymphoblastic lymphoma, seems to be similar to those in any age group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186966.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Cervigni F, Suzuki Y, Ishii T, Hata A: Spatial accessibility to pediatric services. J Community Health; 2008 Dec;33(6):444-8
MedlinePlus Health Information. consumer health - Children's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial accessibility to pediatric services.
  • The objective of this study was to assess spatial accessibility (SA) to pediatric healthcare services at hospitals in Chiba Prefecture, Japan in 2006.
  • SA analysis showed that 98.8% of children distributed within a 10 km TD threshold from a hospital with general pediatric services, and that 82.3% of LB and LBW distributed within a 30 km TD threshold from a hospital with neonatology services.
  • Through the methodology applied, we visualized areas short of pediatric services.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581216.001).
  • [ISSN] 0094-5145
  • [Journal-full-title] Journal of community health
  • [ISO-abbreviation] J Community Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, Zimmermann M, Strauch K, Ludwig WD, Schrappe M, Reiter A: Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma; 2008 Mar;49(3):451-61
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact.
  • This study analyzed loss of heterozygosity (LOH) at chromosome 6q and compared the LOH findings in pediatric precursor T lymphoblastic lymphoma (T-LBL) with the LOH findings in precursor-T lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Chromosomes, Human, Pair 6. Loss of Heterozygosity. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297521.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Liu S, Breit S, Danckwardt S, Muckenthaler MU, Kulozik AE: Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann Hematol; 2009 Jul;88(7):613-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation of Notch1 signaling plays an important role in the pathogenesis of precursor T-cell lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Amyloid Precursor Protein Secretases / physiology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptor, Notch1 / antagonists & inhibitors

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057901.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-(((3,5-difluorophenyl)acetyl)amino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)propanamide; 0 / Benzodiazepinones; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


48. Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A, Skowronska A, Mapp K, Sameith K, Powell JE, Lawson S, Kearns P, Falciani F, Taylor M, Stankovic T: Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood; 2009 Jan 1;113(1):117-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response.
  • The molecular basis of different outcomes in pediatric acute lymphoblastic leukemia (ALL) remains poorly understood.
  • We addressed the clinical significance and mechanisms behind in vitro cellular responses to ionizing radiation (IR)-induced DNA double-strand breaks in 74 pediatric patients with ALL.
  • [MeSH-major] DNA Breaks, Double-Stranded. Gene Expression Regulation, Leukemic. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941120.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


49. Bewley T: Preparation for non medical prescribing: a review. Paediatr Nurs; 2007 Jun;19(5):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation for non medical prescribing: a review.
  • The National Service Framework (England) standards related to medicines for children and young people promote the use of non medical prescribing to improve children's access to appropriate medicines.
  • A project was carried out to evaluate non medical prescribing by paediatric nurses across Merseyside, Manchester and Cheshire in the north west of England.
  • If services are to be delivered in line with best practice guidance there needs to be a comprehensive, standardised medicines management education plan that is initiated in pre-registration nurse training, leading to appropriate education for non-medical prescribing roles.
  • [MeSH-major] Drug Prescriptions. Pediatric Nursing / manpower

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621779.001).
  • [ISSN] 0962-9513
  • [Journal-full-title] Paediatric nursing
  • [ISO-abbreviation] Paediatr Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


50. Amare Kadam PS, Raje GC, Pais AP, Banavali S: Coexistence of ETV6/RUNX1 and MLL aberrations in B-cell precursor acute lymphoblastic leukemia discloses a small subclass of BCP-ALL. Cancer Genet Cytogenet; 2008 Apr 1;182(1):27-32
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of ETV6/RUNX1 and MLL aberrations in B-cell precursor acute lymphoblastic leukemia discloses a small subclass of BCP-ALL.
  • Out of 76 pediatric cases of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) positive for ETV6/RUNX1 (previously TEL/AML1) resulting from t(12;21), 7 cases revealed coexistence of ETV6/RUNX1 and MLL aberrations.
  • ETV6/RUNX1 and MLL aberration clone size in these cases was suggestive of ETV6/RUNX1 as an early primary event, originating in the embryonic or infant stage and developing into leukemia by later acquisition of MLL aberration, ETV6 loss, and ETV6/RUNX1 duplication as secondary events.
  • [MeSH-major] Chromosome Aberrations. Core Binding Factor Alpha 2 Subunit / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328947.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


51. Ceyhan M, Yildirim I, Tekeli A, Yurdakok M, Us E, Altun B, Kutluk T, Cengiz AB, Gurbuz V, Barin C, Bagdat A, Cetinkaya D, Gur D, Tuncel O: A Chryseobacterium meningosepticum outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients. Am J Infect Control; 2008 Aug;36(6):453-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Chryseobacterium meningosepticum outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients.
  • The index patient was from the neonatal intensive care unit, and the older patients were from other pediatric wards.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675153.001).
  • [ISSN] 1527-3296
  • [Journal-full-title] American journal of infection control
  • [ISO-abbreviation] Am J Infect Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / DNA, Bacterial
  •  go-up   go-down


52. Guran T, Turan S, Karadag B, Ersu R, Karakoc F, Bereket A, Dagli E: Bone mineral density in children with non-cystic fibrosis bronchiectasis. Respiration; 2008;75(4):432-6
MedlinePlus Health Information. consumer health - Bone Density.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density in children with non-cystic fibrosis bronchiectasis.
  • Although children with non-CF bronchiectasis have similar risk factors for osteopenia/osteoporosis, data on BMD in this group of patients are lacking.
  • OBJECTIVE: To evaluate BMD in children with non-CF bronchiectasis.
  • METHODS: In this study, we evaluated BMD of the radius and tibia in 32 children (17 girls) with non-CF bronchiectasis and in 23 healthy controls matched for age, sex and pubertal stage by quantitative ultrasound (speed of sound).
  • However, more children with non-CF bronchiectasis had osteopenia (z-scores between -1 and -2 SD) and osteoporosis (z-score <or=2 SD) compared to the control group (62 vs. 30%, p = 0.019).
  • CONCLUSION: Osteopenia is more common in children with non-CF bronchiectasis compared to controls and the risk of osteoporosis and osteopenia increases with age.


53. van Vlierberghe P, Meijerink JP, Lee C, Ferrando AA, Look AT, van Wering ER, Beverloo HB, Aster JC, Pieters R: A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia. Leukemia; 2006 Jul;20(7):1245-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia.
  • Over the last decade, genetic characterization of T-cell acute lymphoblastic leukemia (T-ALL) has led to the identification of a variety of chromosomal abnormalities.
  • In this study, we used array-comparative genome hybridization (array-CGH) and identified a novel recurrent 9q34 amplification in 33% (12/36) of pediatric T-ALL samples, which is therefore one of the most frequent cytogenetic abnormalities observed in T-ALL thus far.
  • [MeSH-major] Chromosomes, Human, Pair 9. Gene Duplication. Leukemia-Lymphoma, Adult T-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673019.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Receptor, Notch1
  •  go-up   go-down


54. Kawamura M, Kaku H, Ito T, Funata N, Taki T, Shimada A, Hayashi Y: FLT3-internal tandem duplication in a pediatric patient with t(8;21) acute myeloid leukemia. Cancer Genet Cytogenet; 2010 Dec;203(2):292-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3-internal tandem duplication in a pediatric patient with t(8;21) acute myeloid leukemia.
  • Patients diagnosed with t(8;21)-acute myeloid leukemia (AML) are currently considered to have good prognoses, but about half of these patients relapse.
  • Even though t(8;21)-AML is less likely to co-occur with FLT3-ITD in pediatric patients, this report suggests that prognostic factors, including FLT3 and KIT genes and the surface marker CD56, should be analyzed in these patients.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Gene Duplication. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21156247.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


55. Xiao C, Su ZL, Wu QL, Gao HY, Fang JC, Xia ZJ, Guan ZZ: [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Jan;34(1):22-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
  • OBJECTIVE: To investigate the clinical and pathological features of non-Hodgkin's lymphoma (NHL) and to evaluate the applicability of the new WHO classification of lymphoid neoplasms.
  • METHODS: According to the new WHO classification, a total of 500 cases of non-Hodgkin's lymphoma diagnosed during the period 1992 - 2003 were reviewed and reappraised with their morphological, immunological and clinical characteristics.
  • Overall, 6 subtypes including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), unspecified peripheral T-cell lymphoma (PT-un), precursor T-lymphoblastic lymphoma (T-LBL), extranodal marginal zone B-cell lymphoma of MALT type (MALT) and B-small lymphocytic lymphoma (B-SLL) were among the most common subtypes.
  • In pediatric and young patient populations, the most common subtypes were LBL, DLBCL and Burkitt's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796877.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


56. Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S, Schwenn M, Shuster J, Link MP, Children's Oncology Group: Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Jul;51(1):29-33
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study.
  • While a high proportion of adults with PTCL have poor risk disease, pediatric PTCL is not well characterized.
  • This study examines the outcome of localized and advanced PTCL in pediatric patients treated in standardized fashion.
  • PROCEDURE: We identified 20 pediatric patients diagnosed with PTCL whose tumor cells did not express CD30 and/or ALK, as determined by immunohistochemistry, between 1992 and 2000 on one of two treatment protocols for localized NHL (POG 9219) or advanced stage large cell lymphoma (POG 9315).

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18300314.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA180899; United States / NCI NIH HHS / CA / U10 CA180886
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS688709; NLM/ PMC4447625
  •  go-up   go-down


57. Arroud M, Afifi MA, El Ghazi K, Nejjari C, Bouabdallah Y: Lung hydatic cysts in children: comparison study between giant and non-giant cysts. Pediatr Surg Int; 2009 Jan;25(1):37-40
Hazardous Substances Data Bank. ALBENDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung hydatic cysts in children: comparison study between giant and non-giant cysts.
  • PURPOSE: The aim of this study is to review our experience in pediatric giant pulmonary hydatid cysts focusing on clinical symptoms, location of the cyst, type of the intervention, postoperative complications and long-term results.
  • Two groups were defined: Group 1, 32 children with giant hydatid cysts and Group 2, 86 children with non-giant cysts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18828025.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiprotozoal Agents; 0 / Saline Solution, Hypertonic; F4216019LN / Albendazole
  •  go-up   go-down


58. Grant AM, Jamieson DJ, Elam-Evans LD, Beck-Sague C, Duerr A, Henderson SL: Reasons for testing and clinical and demographic profile of adolescents with non-perinatally acquired HIV infection. Pediatrics; 2006 Mar;117(3):e468-75
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reasons for testing and clinical and demographic profile of adolescents with non-perinatally acquired HIV infection.
  • Demographic, clinical, behavioral, and HIV testing data were abstracted from medical charts of 59 non-perinatally HIV-infected adolescents who were aged 13 to 18 years and entered care at the pediatric and adolescent HIV clinic of a Georgia hospital during 1999-2002.
  • Adolescents whose HIV was diagnosed at non-health care facilities entered HIV care much later than adolescents whose HIV was diagnosed at health care facilities (median: 108 vs 25 days).
  • CONCLUSIONS: Strategies are needed to implement timely linkage to medical services of adolescents who receive a diagnosis of HIV infection at non-health care facilities and to increase HIV testing, prevention efforts, and recognition of recent HIV infection among sexually active adolescents.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510625.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kadan-Lottick NS, Zeltzer LK, Liu Q, Yasui Y, Ellenberg L, Gioia G, Robison LL, Krull KR: Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst; 2010 Jun 16;102(12):881-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.
  • BACKGROUND We sought to measure self-reported neurocognitive functioning among survivors of non-central nervous system (CNS) childhood cancers, overall and compared with a sibling cohort, and to identify factors associated with worse functioning.
  • METHODS In a retrospective cohort study, 5937 adult survivors of non-CNS cancers and 382 siblings completed a validated neuropsychological instrument with subscales in task efficiency, emotional regulation, organization, and memory.
  • Non-CNS cancer survivors and siblings were compared with multivariable linear regression and log-binomial regression.
  • RESULTS Non-CNS cancer survivors had similar or slightly worse (<0.5 standard deviation) mean test scores for all four subscales than siblings.
  • Impaired task efficiency was most often identified in patients with acute lymphoblastic leukemia who received cranial radiation therapy (18.1% with impairment), myeloid leukemia who received cranial radiation therapy (21.2%), and non-Hodgkin lymphoma (13.9%).
  • CONCLUSION A statistically and clinically significantly higher percentage of self-reported neurocognitive impairment was found among survivors of non-CNS cancers than among siblings.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1207-13 [11309635.001]
  • [Cites] Psychosomatics. 2001 May-Jun;42(3):241-6 [11351113.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1539-45 [11402112.001]
  • [Cites] Child Neuropsychol. 2000 Sep;6(3):235-8 [11419452.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1015-8 [6118478.001]
  • [Cites] Pediatrics. 1985 Apr;75(4):745-53 [3838584.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):315-20 [3422262.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):74-86 [2496615.001]
  • [Cites] Dev Med Child Neurol. 1990 Mar;32(3):238-48 [2311827.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Pediatr. 1992 Dec;121(6):885-9 [1447650.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] J Pediatr Psychol. 2005 Jan-Feb;30(1):65-78 [15610986.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):281-90 [15806539.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1742-5 [17148777.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4914-21 [17971588.001]
  • [Cites] Pediatrics. 2007 Nov;120(5):e1229-36 [17974716.001]
  • [Cites] Neuropsychol Rev. 2008 Jun;18(2):121-31 [18415683.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3025-30 [18565888.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):159-64 [18680151.001]
  • [Cites] J Int Neuropsychol Soc. 2009 Jan;15(1):31-41 [19128526.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2308-18 [19364948.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2626-35 [19815636.001]
  • [Cites] Neuropsychology. 2009 Nov;23(6):705-17 [19899829.001]
  • [Cites] Eur J Pharmacol. 2010 Jan 10;626(1):83-6 [19835870.001]
  • [CommentIn] J Natl Cancer Inst. 2011 Apr 6;103(7):607; author reply 607-9 [21350219.001]
  • (PMID = 20458059.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024138; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886093
  •  go-up   go-down


60. Stams WA, Beverloo HB, den Boer ML, de Menezes RX, Stigter RL, van Drunen E, Ramakers-van-Woerden NL, Loonen AH, van Wering ER, Janka-Schaub GE, Pieters R: Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia; 2006 Mar;20(3):410-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.
  • Clinical heterogeneity within t(12;21) or TEL/AML1-positive ALL (25% of childhood common/preB ALL) indicates that additional genetic changes might contribute to outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424874.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


61. Glass KC, Binik A: Rethinking risk in pediatric research. J Law Med Ethics; 2008;36(3):567-76
MedlinePlus Health Information. consumer health - Children's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rethinking risk in pediatric research.
  • This article reviews four areas of pediatric research in which we have identified questionable levels of allowable risk, exceeding those foreseen by the Commission.
  • While embracing the imperative to include children in research is an encouraging step towards providing the pediatric population with effective medical care and finally eradicating the therapeutic orphan, we must ensure that this research does not become overly permissive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840250.001).
  • [ISSN] 1073-1105
  • [Journal-full-title] The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • [ISO-abbreviation] J Law Med Ethics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Chabay P, De Matteo E, Lorenzetti M, Barón AV, Valva P, Preciado MV: Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series. Pediatr Dev Pathol; 2009 Jan-Feb;12(1):28-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series.
  • T-cell non-Hodgkin's lymphomas (NHLs) represent 10% to 15% of all diagnosed lymphomas in Western countries.
  • Our aims were to assess EBV and p53 expression in Argentine pediatric T-cell lymphoma and to correlate them with patients' survival.
  • Epstein-Barr encoded RNAs (EBERs) in situ hybridization and LMP1 and p53 immunohistochemical staining were performed on formalin-fixed paraffin-embedded lymph node biopsies from 25 pediatric T-lymphoma patients.
  • Epstein-Barr virus expression was found in 8.0% of cases. p53-positive staining was distributed in 92% of pediatric cases.
  • Our data showed a low frequency of EBV association with pediatric T-cell lymphoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epstein-Barr Virus Infections / epidemiology. Leukemia, T-Cell / metabolism. Leukemia, T-Cell / virology. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540692.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


63. Hooper E, Hawkins DM, Kowalski RJ, Post DR, Britz JA, Brooks KC, Turman MA: Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant; 2005 Dec;19(6):834-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing pediatric immune response zones using the Cylex ImmuKnow assay.
  • In this study, we determined the normal ranges for the ImmuKnow assay in healthy children and compared those values to levels obtained in healthy adults and in stable pediatric renal transplant patients.
  • Thus, this study provides critical information necessary to utilize the ImmuKnow assay with pediatric patients.
  • If further studies in pediatric patients document the same and is true for children, then the ImmuKnow assay will provide a useful adjunct tool to prevent over- or under-immunosuppression as newly developed drugs are utilized or drug treatment is altered because of drug side effects, toxicity, concurrent illnesses or rejection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313333.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Mitogens; 0 / Phytohemagglutinins
  •  go-up   go-down


64. Dembowska-Baginska B, Perek D, Brozyna A, Wakulinska A, Olczak-Kowalczyk D, Gladkowska-Dura M, Grajkowska W, Chrzanowska KH: Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer; 2009 Feb;52(2):186-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).
  • BACKGROUND: Due to small number of patients with Nijmegen Breakage Syndrome (NBS) and Non-Hodgkin lymphoma (NHL) experience in their treatment is limited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Nijmegen Breakage Syndrome / complications


65. Coleman DL: The legal ethics of pediatric research. Duke Law J; 2007 Dec;57(3):517-624
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The legal ethics of pediatric research.
  • This move reverses longstanding policy within that community generally to exclude healthy children from such protocols on the grounds that the research as to them is non-therapeutic, that they are particularly vulnerable to research-related abuses, and that they are unable themselves to give informed consent to their participation.
  • The research community's new posture has been supported by prominent pediatric bioethicists who have argued that unless healthy children are included as research subjects in harmful or risky research, the pediatric population will continue to suffer relative to the adult population in the extent to which it benefits from modern advances in science and medicine.
  • In their view, it is possible for the research community to self-administer a rule that strikes a balance between protecting healthy children from research-related abuses and allowing their inclusion in cutting-edge pediatric research.
  • This Article explores the flaws inherent in this ethics of pediatric research.
  • Second, in its failure to assure that the burdens of non-therapeutic research are not placed disproportionately on children of lower socioeconomic and minority status, it violates the antidiscrimination principle, which has only begun to make good on its promise of equal treatment for all children.
  • Ultimately, this Article argues that harmonization of the rules governing pediatric research with the law of child protection and parents' consent authority is the best way to assure that children are protected in the research setting in these respects and to the same extent they are otherwise in the society.

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18354870.001).
  • [ISSN] 0012-7086
  • [Journal-full-title] Duke law journal
  • [ISO-abbreviation] Duke Law J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Rohlman DS, Bodner T, Arcury TA, Quandt SA, McCauley L: Developing methods for assessing neurotoxic effects in Hispanic non-English speaking children. Neurotoxicology; 2007 Mar;28(2):240-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing methods for assessing neurotoxic effects in Hispanic non-English speaking children.
  • We have developed a battery to assess neurobehavioral performance in non-English speaking Hispanic children ages 4 years and older.
  • The battery consists of computerized tests from the Behavioral Assessment and Research System, tests selected from the Pediatric Environmental Neurobehavioral Test Battery, and the Object Memory Test.
  • This study has demonstrated the utility of using this test battery to assess cognitive and motor performance in non-English speaking Hispanic children.

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759705.001).
  • [ISSN] 0161-813X
  • [Journal-full-title] Neurotoxicology
  • [ISO-abbreviation] Neurotoxicology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Environmental Pollutants
  •  go-up   go-down


67. Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group: The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer; 2008 Aug;51(2):188-92
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.
  • BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, B-Cell / therapy. Lymphoma, B-Cell / therapy


68. Calaminus G, Hense B, Laws HJ, Groeger M, MacKenzie CR, Göbel U: Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92. Klin Padiatr; 2007 Nov-Dec;219(6):355-60
Genetic Alliance. consumer health - Tetanus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92.
  • BACKGROUND: Children and adolescents after acute lymphoblastic leukemia are at risk for a prolonged period of immunodeficiency.
  • [MeSH-major] Antibodies, Bacterial / blood. Diphtheria Toxoid / immunology. Immunologic Memory. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology

  • Genetic Alliance. consumer health - Diphtheria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050047.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Diphtheria Toxoid; 0 / Tetanus Toxoid
  •  go-up   go-down


69. Hiippala A, Serwer GA, Clausson E, Davenport L, Brand T, Happonen JM: Automatic atrial threshold measurement and adjustment in pediatric patients. Pacing Clin Electrophysiol; 2010 Mar;33(3):309-13
MedlinePlus Health Information. consumer health - Congenital Heart Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automatic atrial threshold measurement and adjustment in pediatric patients.
  • The purpose of the study was to assess Atrial Capture Management (ACM) of Medtronic pacemakers in pediatric patients.
  • CONCLUSIONS: ACM measures atrial thresholds reliably in pediatric patients with both endocardial and epicardial leads, allowing its use in both.

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954505.001).
  • [ISSN] 1540-8159
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Woods DM, Holl JL, Angst DB, Echiverri SC, Johnson D, Soglin DF, Srinivasan G, Amsden LB, Barnathan J, Hason T, Lamkin L, Weiss KB: Gaps in pediatric clinician communication and opportunities for improvement. J Healthc Qual; 2008 Sep-Oct;30(5):43-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gaps in pediatric clinician communication and opportunities for improvement.
  • Sixty-three focus groups were conducted with clinicians from five Chicago Pediatric Patient Safety Consortium hospitals.
  • Results of this investigation highlighted gaps in pediatric clinician communication and opportunities for improvement.
  • [MeSH-major] Hospitals, Pediatric / standards. Interdisciplinary Communication. Quality Assurance, Health Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831476.001).
  • [ISSN] 1062-2551
  • [Journal-full-title] Journal for healthcare quality : official publication of the National Association for Healthcare Quality
  • [ISO-abbreviation] J Healthc Qual
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Laupland KB, Gregson DB, Vanderkooi OG, Ross T, Kellner JD: The changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-2006. Pediatr Infect Dis J; 2009 Feb;28(2):114-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-2006.
  • BACKGROUND: The epidemiology of pediatric bloodstream infection has not been well defined in general populations.
  • The primary objective of this study was to describe the burden of illness of pediatric bloodstream infections in a large Canadian region and secondarily to assess the effect of implementation of universal infant immunization with 7-valent pneumococcal conjugate vaccine (PCV7) in 2002.
  • METHODS: Surveillance for all bloodstream infections was conducted among pediatric (<18 years) residents of the Calgary Health Region during 2000-2006.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19116605.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Korostenskaja M, Pardos M, Fujiwara H, Kujala T, Horn P, Rose D, Byars A, Brown D, Seo JH, Wang Y, Vannest J, Xiang J, Degrauw T, Näätänen R, Lee KH: Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy. Epilepsy Res; 2010 Nov;92(1):63-73
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuromagnetic evidence of impaired cortical auditory processing in pediatric intractable epilepsy.
  • PURPOSE: We aimed to determine the changes in neural correlates of auditory information processing such as auditory detection, encoding, and sensory discrimination in pediatric patients with intractable epilepsy.

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20863661.001).
  • [ISSN] 1872-6844
  • [Journal-full-title] Epilepsy research
  • [ISO-abbreviation] Epilepsy Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR: Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res; 2008 May 15;14(10):3204-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of pediatric gastrointestinal stromal tumors.
  • PURPOSE: Pediatric gastrointestinal stromal tumors (GIST) are rare and occur preferentially in females as multifocal gastric tumors, typically lacking mutations in KIT and PDGFRA.
  • As KIT oncoprotein is consistently overexpressed in pediatric GIST, we sought to investigate the activation of KIT downstream targets and alterations of KIT/PDGFRA gene copy number, mine novel therapeutic targets by gene expression, and test tyrosine kinase receptor activation by proteomic profiling.
  • EXPERIMENTAL DESIGN: Seventeen pediatric GISTs were investigated for KIT/PDGFRA genotype and biochemical activation of KIT downstream targets.
  • The transcriptional profile of 13 nodules from 8 pediatric patients was compared with 8 adult wild-type (WT) GISTs, including 3 young adults.
  • Pediatric GISTs showed a distinct transcriptional signature, with overexpression of BAALC, PLAG1, IGF1R, FGF4, and NELL1.
  • CONCLUSIONS: Rare cases of pediatric GIST may occur in male patients and harbor activating KIT/PDGFRA mutations.
  • Pediatric GISTs show distinct transcriptional signature, suggesting a different biology than WT GIST in adults.
  • In vitro drug screening showed that second-generation kinase inhibitors may provide greater clinical benefit in pediatric GIST.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2097-101 [15956962.001]
  • [Cites] Hum Pathol. 2005 May;36(5):486-93 [15948115.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:143-50 [16304372.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2622-7 [16638875.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1093-103 [16624552.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Sep;45(9):820-8 [16736500.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):170-81 [17200352.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2369-77 [17438095.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2938-43 [17535989.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5693-701 [17353898.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):254-8 [17262795.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):79-88 [17667967.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5278-83 [11016658.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):955-62 [11549588.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1289-97 [11555676.001]
  • [Cites] Am J Med Genet. 2002 Mar 1;108(2):132-9 [11857563.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3474-82 [12444079.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4710-22 [12879016.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3329-37 [12960119.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):1051-6 [14585369.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):179-91 [14712223.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):689-95 [15010069.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2655-60 [15231574.001]
  • [Cites] N Engl J Med. 1977 Jun 30;296(26):1517-8 [865533.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8318-23 [8710868.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):224-35 [15826837.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):179-87 [15838387.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jul;45(1):20-4 [15795882.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1373-81 [16160481.001]
  • (PMID = 18483389.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / HL/DK55748; United States / NCI NIH HHS / CA / R01 CA102774; United States / NCI NIH HHS / CA / P01CA47179; United States / NCI NIH HHS / CA / CA102613; United States / NCI NIH HHS / CA / R01 CA102613; United States / NIDDK NIH HHS / DK / R01 DK055748; United States / NCI NIH HHS / CA / CA102774; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS515417; NLM/ PMC3805121
  •  go-up   go-down


74. Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ: Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer; 2009 Aug;53(2):184-90
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.

  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2009 Dec 15;53(7):1359; author reply 1360 [19533652.001]
  • (PMID = 19353621.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


75. Kim MJ, Yoon HS, Cho SY, Lee HJ, Suh JT, Lee J, Yoon HJ, Lee WI, Park TS: ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia. Cancer Genet Cytogenet; 2010 Sep;201(2):116-21
Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
  • Although acute promyelocytic leukemia (APL) has been regarded as a serious medical emergency associated with disseminated intravascular coagulopathy or subsequent mortality, it is now considered a curable leukemia that is particularly sensitive to treatment with all-trans retinoic acid combined with chemotherapy.
  • However, it is not clear whether additional chromosomal abnormalities in APL patients directly influence the prognosis or treatment response. ider(17)(q10)t(15;17)(q22;q21) has mostly been reported in adult APL patients, and only three cases of pediatric APL associated with ider(17)(q10)t(15;17) showing poor prognosis have been described in the literature.
  • Here, we report the close follow-up (clinical and laboratory) data of a pediatric APL case associated with ider(17)(q10)t(15;17).
  • Although based on a limited amount of data (four pediatric APL cases), such results in pediatric APL patients may provide important insight into the relationship between ider(17)(q10)t(15;17) and poor prognosis.
  • However, further well-designed case-control studies are necessary to determine the treatment response and prognosis in pediatric or adult APL patients with ider(17)(q10)t(15;17).
  • [MeSH-major] Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20682396.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human
  •  go-up   go-down


76. Karrman K, Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Ehrencrona H, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Palmqvist L, Johansson B, Nordic Society of Pediatric Hematology, Oncology (NOPHO), Swedish Cytogenetic Leukemia Study Group (SCLSG), NOPHO Leukemia Cytogenetic Study Group (NLCSG): Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer; 2009 Sep;48(9):795-805
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome.
  • Clinical characteristics and cytogenetic aberrations were ascertained and reviewed in a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias (T-ALLs) diagnosed between 1992 and 2006 in the Nordic countries.
  • In conclusion, in this large series of childhood T-ALLs from the Nordic countries, the cytogenetic findings were not associated with risk of therapy failure with the exception of the TCR;other group.
  • [MeSH-major] Chromosome Aberrations. Gene Rearrangement, T-Lymphocyte. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530250.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


77. Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Odaka H, Owada M: Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol; 2008 Sep;23(9):1461-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.
  • For this reason, we developed non-invasive methods for measuring urinary alpha-galactosidase A (alpha-gal A) protein, using enzyme-linked immunosorbent assay (ELISA), and for globotriaosylceramide (GL-3), using tandem mass spectrometry (MS/MS).

  • Genetic Alliance. consumer health - BabyFirstTest - Fabry Disease.
  • Genetic Alliance. consumer health - Fabry Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535844.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide; EC 3.2.1.22 / alpha-Galactosidase
  •  go-up   go-down


78. Bardini M, Spinelli R, Bungaro S, Mangano E, Corral L, Cifola I, Fazio G, Giordan M, Basso G, De Rossi G, Biondi A, Battaglia C, Cazzaniga G: DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia; 2010 Jan;24(1):169-76
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathogenesis of infant acute lymphoblastic leukemia (ALL) is still not well defined.
  • Short latency to leukemia and very high concordance rate for ALL in Mixed-Lineage Leukemia (MLL)-positive infant twins suggest that the MLL rearrangement itself could be sufficient for overt leukemia.
  • Attempts to generate a suitable mouse model for MLL-AF4-positive ALL did not thoroughly resolve the issue of whether cooperating mutations are required to reduce latency and to generate overt leukemia in vivo.
  • In contrast to pediatric, adolescent and adult ALL cases, the MLL rearrangement in infant ALL is associated with an exceptionally low frequency of copy-number abnormalities, thus confirming the unique nature of this disease.
  • It can be argued that the MLL rearrangement as a first hit, rather than inducing the acquisition of additional genetic lesions, has a major role to drive and hasten the onset of leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Gene Dosage. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907438.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


79. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER, Veerman AJ, Kamps WA, Meijerink JP, Pieters R: The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood; 2006 Nov 15;108(10):3520-9
Genetic Alliance. consumer health - Pediatric T-cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.
  • To identify new cytogenetic abnormalities associated with leukemogenesis or disease outcome, T-cell acute lymphoblastic leukemia (T-ALL) patient samples were analyzed by means of the array-comparative genome hybridization technique (array-CGH).
  • Here, we report the identification of a new recurrent and cryptic deletion on chromosome 11 (del(11)(p12p13)) in about 4% (6/138) of pediatric T-ALL patients.
  • LMO2 abnormalities represent about 9% (13/138) of pediatric T-ALL cases and are more frequent in pediatric T-ALL than appreciated until now.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 11. DNA-Binding Proteins / metabolism. Metalloproteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16873670.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


80. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood; 2008 May 1;111(9):4477-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
  • The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification.
  • Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased.
  • Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood. 2009 Apr 30;113(18):4478. Dosage error in article text
  • (PMID = 18285545.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  • [Investigator] Beck J; Bode U; Boos J; Feldges A; Gadner H; Havers W; Henze G; Kornhuber B; Kühl J; Lampert F; Maass E; Mittler U; Niemeyer C; Niethammer D; Niggli F; Reiter A; Riehm H; Ritter J; Schrappe M; Urban C; Wehinger H; Welte K; Zintl F; Mertens R; Imbach R; Signer E; Heidemann P; Rager K; Imbach P; Wündisch GF; Henze G; Gaedicke G; Dörffel W; Bode U; Eberl W; Mau G; Jacobi H; Hofmann K; Thaben JD; Möbius D; Andler W; Niekrens C; Breu H; Scharfe V; Zickler P; Weinmann G; Beck JD; Havers W; Kremens B; Müller G; Kornhuber B; Niemeyer C; Reiter A; Lampert F; Lakomek M; Urban C; Gerein V; Exadaktylos P; Burdach S; Riehm H; Welte K; Selle B; Tautz Ch; Graf N; Dengg K; Zintl F; Gutwein FJ; Nessler G; Dupuis W; Wehinger H; Rodehüser M; Kaulfersch W; Rister M; Berthold F; Schneppenheim R; Suttorp M; Sternschulte W; Garcia RM; Domula M; Mutz I; Moser R; Schmitt K; Ebetsberger G; Stöllinger O; Nobile Buetti L; Bucsky P; Dominick HC; Caflisch U; Mittler U; Sauer O; Christiansen H; Tillmann W; Müller-Weihrich S; Bender-Götze C; Jürgens H; Ritter J; Jobke A; Schwarzer U; Schofer O; Eggers G; Treuner J; Geib R; Jones N; Dickerhoff R; Neubert D; Göbel FJ; Ploier R; Feldges A; Greiner J; Rauh W; Niethammer D; Klingebiel T; Debatin KM; Kleihauer E; Franke D; Gadner H; Peters Ch; Mann G; Otte J; Kühl J; Krohn HP; Niggli F
  •  go-up   go-down


81. Seidemann K, Book M, Zimmermann M, Meyer U, Welte K, Stanulla M, Reiter A: MTHFR 677 (C--&gt;T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol; 2006 May;85(5):291-300
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
  • We analyzed the relationship of genetic variation within the methylenetetrahydrofolate reductase gene (MTHFR 677 C-->T) with clinical characteristics, outcome, and therapy-related toxicity in pediatric non-Hodgkin's lymphoma (NHL) in our multicenter trial NHL-BFM 95.
  • In this trial, high-dose methotrexate (MTX) infusion regimens were randomized (4- vs 24-h infusion) in patients with B-cell lymphoma; MTX was applied as 24-h infusion in all patients with lymphoblastic lymphoma and anaplastic large cell lymphoma.
  • The genotypes in 484 pediatric patients were distributed as follows: MTHFR 677 CC, 206 patients (42.6%); MTHFR 677 CT, 214 patients (44.2%); and MTHFR 677 TT, 64 patients (13.2%).
  • Lymphoblastic lymphoma was significantly associated with homozygosity for the MTHFR 677 T allele.
  • Therefore, we conclude that the MTHFR 677 C-->T polymorphism does not appear to influence outcome or therapy-associated toxicity in pediatric patients with NHL treated on BFM protocols.
  • [MeSH-major] Alleles. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859561 for PMID:16463153 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16463153.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


82. Mann G, Attarbaschi A, Steiner M, Simonitsch I, Strobl H, Urban C, Meister B, Haas O, Dworzak M, Gadner H, Austrian Berlin-Frankfurt-Münster (BFM) Group: Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping. Pediatr Hematol Oncol; 2006 Apr-May;23(3):167-76
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping.
  • Non-Hodgkin lymphoma (NHL) represents one of the most rapidly growing malignancies in childhood and adolescence.
  • The authors identified 23 patients with Burkitt lymphoma by the combination of FAB L3 morphology and a mature B-cell phenotype and 22 patients with lymphoblastic lymphoma by FAB L1/L2 morphology and a T-/B-cell precursor phenotype.
  • Burkitt lymphoma, lymphoblastic lymphoma, and, in a few cases, some large cell lymphomas could be classified reliably by cytomorphology and immunophenotyping of freshly obtained tumor cell material, enabling an early start of specific lymphoma treatment.
  • [MeSH-major] Cytological Techniques. Flow Cytometry. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Abdominal Neoplasms / classification. Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / pathology. Adolescent. Antigens, CD / analysis. Austria / epidemiology. Biopsy, Fine-Needle. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Cell Nucleus / ultrastructure. Cell Size. Child. Child, Preschool. Cytoplasm / ultrastructure. Early Diagnosis. Feasibility Studies. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Lymphocyte Subsets / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Mediastinal Neoplasms / classification. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prospective Studies. Staining and Labeling


83. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • CONCLUSION: Six percent of childhood/adolescent NHL patients were CNS positive.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Caetano SC, Silveira CM, Kaur S, Nicoletti M, Hatch JP, Brambilla P, Sassi R, Axelson D, Keshavan MS, Ryan ND, Birmaher B, Soares JC: Abnormal corpus callosum myelination in pediatric bipolar patients. J Affect Disord; 2008 Jun;108(3):297-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal corpus callosum myelination in pediatric bipolar patients.
  • Here we compared the callosal signal intensity of children and adolescents with bipolar disorder to that of matched healthy subjects, to investigate the hypothesis that callosal myelination is abnormal in pediatric bipolar patients.

  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Psychiatry. 1989 Nov;26(7):659-68 [2804188.001]
  • [Cites] Biol Psychiatry. 1990 Jun 1;27(11):1188-96 [2354225.001]
  • [Cites] Brain Res Dev Brain Res. 1996 Feb 26;91(2):274-80 [8852379.001]
  • [Cites] Brain. 1989 Jun;112 ( Pt 3):799-835 [2731030.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):525-31 [16018982.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):221-5 [14742592.001]
  • [Cites] Life Sci. 2002 Mar 8;70(16):1909-22 [12005176.001]
  • [Cites] Biol Psychiatry. 2003 Dec 1;54(11):1294-7 [14643097.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1999 May;23(4):571-88 [10390717.001]
  • [Cites] Cogn Behav Neurol. 2003 Mar;16(1):75-81 [14765004.001]
  • [Cites] Psychiatry Res. 2006 Jan 30;146(1):83-5 [16337778.001]
  • (PMID = 18037496.001).
  • [ISSN] 0165-0327
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / P30 MH030915; United States / NIMH NIH HHS / MH / MH55123; United States / NCRR NIH HHS / RR / K24 RR020571-04; United States / NIMH NIH HHS / MH / MH30915; United States / NCRR NIH HHS / RR / K24 RR020571-01A1; United States / NCRR NIH HHS / RR / RR020571-03; United States / NCRR NIH HHS / RR / RR020571-05; United States / NIMH NIH HHS / MH / MH069774-02; United States / NCRR NIH HHS / RR / RR020571-01A1; United States / NIMH NIH HHS / MH / R01 MH069774-02; United States / NIMH NIH HHS / MH / R01 MH069774-04; United States / NIMH NIH HHS / MH / K23 MH001736-05; United States / NIMH NIH HHS / MH / R01 MH069774; United States / NCRR NIH HHS / RR / K24 RR020571; United States / NIMH NIH HHS / MH / MH069774-01A2; United States / NIMH NIH HHS / MH / R01 MH059929; United States / NCRR NIH HHS / RR / K24 RR020571-03; United States / NCRR NIH HHS / RR / RR020571-02; United States / NIMH NIH HHS / MH / MH001736-04; United States / NIMH NIH HHS / MH / K23 MH001736-04; United States / NIMH NIH HHS / MH / MH01736; United States / NIMH NIH HHS / MH / MH068662; United States / NIMH NIH HHS / MH / K23 MH001736; United States / NIMH NIH HHS / MH / MH001736-03; United States / NIMH NIH HHS / MH / P20 MH068662; United States / NIMH NIH HHS / MH / K23 MH001736-03; United States / NCRR NIH HHS / RR / K24 RR020571-02; United States / NIMH NIH HHS / MH / MH59929; United States / NIMH NIH HHS / MH / MH069774-04; United States / NCRR NIH HHS / RR / K24 RR020571-05; United States / NIMH NIH HHS / MH / R01 MH069774-01A2; United States / NIMH NIH HHS / MH / P30 MH055123; United States / NIMH NIH HHS / MH / R01 MH069774-03; United States / NIMH NIH HHS / MH / MH001736-05; United States / NCRR NIH HHS / RR / RR020571-04; United States / NCRR NIH HHS / RR / RR020571; United States / NIMH NIH HHS / MH / MH069774-03; United States / NIMH NIH HHS / MH / MH69774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS52562; NLM/ PMC2677111
  •  go-up   go-down


85. Carrasco X, Castillo S, Aravena T, Rothhammer P, Aboitiz F: Williams syndrome: pediatric, neurologic, and cognitive development. Pediatr Neurol; 2005 Mar;32(3):166-72
MedlinePlus Health Information. consumer health - Developmental Disabilities.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Williams syndrome: pediatric, neurologic, and cognitive development.
  • Initial pediatric signs are developmental delay and nocturnal irritability.


86. Hotfilder M, Röttgers S, Rosemann A, Schrauder A, Schrappe M, Pieters R, Jürgens H, Harbott J, Vormoor J: Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res; 2005 Feb 15;65(4):1442-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells.
  • Open questions in the pathogenesis of childhood acute lymphoblastic leukemia (ALL) are which hematopoietic cell is target of the malignant transformation and whether primitive stem cells contribute to the leukemic clone.
  • Fluorescence in situ hybridization analysis, however, shows that none of these myeloid colonies (0 of 41 RT-PCR-positive colonies) originated from a progenitor cell that carries the leukemia-specific translocation.
  • In conclusion, we show that childhood high-risk ALL/t(9;22) and t(4;11) originate in a primitive CD34(+)CD19(-) progenitor/stem cell without a myeloerythroid developmental potential.
  • [MeSH-major] Antigens, CD19 / biosynthesis. Antigens, CD34 / biosynthesis. Neoplastic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 4 / genetics. Chromosomes, Human, Pair 9 / genetics. Flow Cytometry. Genes, abl / genetics. Humans. In Situ Hybridization, Fluorescence. Myeloid-Lymphoid Leukemia Protein. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735032.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


87. Barbaric D, Wynne K, Aslanian S, Bond M, Reid GS: Immune evasion strategies of pediatric precursor-B acute lymphoblastic leukemia after allogeneic bone marrow transplantation-a case study. Leuk Res; 2005 Jun;29(6):711-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune evasion strategies of pediatric precursor-B acute lymphoblastic leukemia after allogeneic bone marrow transplantation-a case study.
  • Bone marrow transplantation (BMT) is the primary curative option for refractory/relapsed pediatric acute lymphoblastic leukemia.
  • In this study, we compared allogeneic T cell stimulation induced by sequentially obtained precursor-B acute lymphoblastic leukemia (ALL) samples from a single patient with overt graft versus leukemia (GVL) activity.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tumor Escape / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863213.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD137; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF9 protein, human
  •  go-up   go-down


88. Accordi B, Pillozzi S, Dell'Orto MC, Cazzaniga G, Arcangeli A, Kronnie GT, Basso G: Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation. J Biol Chem; 2007 Oct 5;282(40):29384-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation.
  • Expression of c-MET, the HGF (hepatocyte growth factor) tyrosine kinase receptor, was investigated in pediatric B-acute lymphoblastic leukemia (ALL) patients. c-MET was found to be expressed in normal B cells and in B-ALL patients with the t(12;21) TEL-AML1 translocation, but it is not expressed in the most part of B-ALL without the t(12;21).
  • REH cells prestimulated with HGF and treated with doxorubicin had shown a higher apoptotic rate than non-HGF-prestimulated ones (p = 0.03).
  • [MeSH-major] Antigens, CD95 / metabolism. Apoptosis. Core Binding Factor Alpha 2 Subunit / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Proto-Oncogene Proteins c-ets / metabolism. Proto-Oncogene Proteins c-met / metabolism. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673463.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD95; 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Interleukin-3; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 63231-63-0 / RNA; 80168379AG / Doxorubicin; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


89. Boor R, Jacobs J, Hinzmann A, Bauermann T, Scherg M, Boor S, Vucurevic G, Pfleiderer C, Kutschke G, Stoeter P: Combined spike-related functional MRI and multiple source analysis in the non-invasive spike localization of benign rolandic epilepsy. Clin Neurophysiol; 2007 Apr;118(4):901-9
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined spike-related functional MRI and multiple source analysis in the non-invasive spike localization of benign rolandic epilepsy.
  • Clinical studies in patients with non-idiopathic focal epilepsies may clarify whether both techniques can be used as complementary clinical tools to localize the onset of interictal epileptic activity in focal epilepsies.

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317297.001).
  • [ISSN] 1388-2457
  • [Journal-full-title] Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • [ISO-abbreviation] Clin Neurophysiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


90. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP: NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia; 2010 Dec;24(12):2014-22
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
  • Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW7 is a frequent phenomenon in T-cell acute lymphoblastic leukemia (T-ALL).
  • We retrospectively investigated the relevance of NOTCH1/FBXW7 mutations for pediatric T-ALL patients enrolled on Dutch Childhood Oncology Group (DCOG) ALL7/8 or ALL9 or the German Co-Operative Study Group for Childhood Acute Lymphoblastic Leukemia study (COALL-97) protocols.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2010 Dec;24(12):2003-4 [21157484.001]
  • (PMID = 20861909.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / TLX3 protein, human; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; VB0R961HZT / Prednisone
  •  go-up   go-down


91. Huang S, Crawford JB, Porco T, Rutar T: Clinicopathologic review of pediatric enucleations during the last 50 years. J AAPOS; 2010 Aug;14(4):328-33
MedlinePlus Health Information. consumer health - Eye Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic review of pediatric enucleations during the last 50 years.
  • PURPOSE: To evaluate diagnoses leading to enucleations in the pediatric age group over time.
  • The main outcome measures were the frequency of pediatric enucleation specimens in each diagnostic category as compared with total pathological laboratory volume over time, and the age and gender distribution of histopathological diagnostic categories over time.
  • RESULTS: Specimens of 746 eyes from 729 pediatric patients were analyzed.
  • Pediatric enucleated eyes constituted 2.7% of all specimens received at the pathology laboratory.
  • The overall frequency of pediatric enucleation specimens did not change over time.
  • Beginning in the 1980s, pediatric enucleations caused by nonrhegmatogenous retinal detachment, nematode and non-nematode endophthalmitis, and congenital glaucoma decreased significantly.
  • CONCLUSIONS: A decrease in pediatric nonretinoblastoma enucleations was observed over time, possibly attributable to better diagnostic capabilities, surgical techniques, and public health interventions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20736124.001).
  • [ISSN] 1528-3933
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY002162-31
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Rajan GP, Ambett R, Wun L, Dhepnorrarat RC, Kuthubutheen J, Chow Z, Wood B: Preliminary outcomes of cholesteatoma screening in children using non-echo-planar diffusion-weighted magnetic resonance imaging. Int J Pediatr Otorhinolaryngol; 2010 Mar;74(3):297-301
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary outcomes of cholesteatoma screening in children using non-echo-planar diffusion-weighted magnetic resonance imaging.
  • Insights into the DW MRI appearances of postoperative or inflammatory mucosal changes have recently described using non-echo-planar, turbo spin-echo (TSE) DW MRI which reliably distinguishes between postoperative changes and cholesteatoma.
  • We investigated the use of TSE DW MRI in our pediatric population in order to validate a rapid and cost-effective MRI sequence that can be used to screen for cholesteatoma.
  • METHODS: Prospective comparative study with adult and pediatric patients at a tertiary referral centre.
  • RESULTS: In a cohort of 92 patients, 21 pediatric patients were identified.
  • CONCLUSION: TSE (HASTE) DW MRI is emerging as a cost effective, noninvasive alternative to second look surgery for detection and screening for cholesteatoma in pediatric patients.

  • Genetic Alliance. consumer health - Cholesteatoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20079940.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


93. Ben-Youssef R, Baron PW, Sahney S, Weissman J, Baqai W, Franco E, Kore A, Trimzi M, Ojogho O: The impact of intercurrent EBV infection on ATP levels in CD4+ T cells of pediatric kidney transplant recipients. Pediatr Transplant; 2009 Nov;13(7):851-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of intercurrent EBV infection on ATP levels in CD4+ T cells of pediatric kidney transplant recipients.
  • According to published reports, median ImmuKnow is 258 ng/mL in stable pediatric kidney transplant (PKT) recipients > or =12 yr, and 165 ng/mL in those <12 yr.
  • Overall mean ImmuKnow in the nine EBV viremic patients was higher than that in the 19 non-viremic ones (422 +/- 176 ng/mL, and 302 +/- 113 ng/mL, respectively, unequal variance t-test, p = 0.08).

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017293.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


94. Borenstein SH, To T, Wajja A, Langer JC: Effect of subspecialty training and volume on outcome after pediatric inguinal hernia repair. J Pediatr Surg; 2005 Jan;40(1):75-80
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of subspecialty training and volume on outcome after pediatric inguinal hernia repair.
  • The aim of this study was to determine if there are any differences in outcome when this procedure is performed by subspecialist pediatric surgeons when compared with general surgeons.
  • METHODS: All pediatric inguinal hernias repaired in the province of Ontario between 1993 and 2000 were reviewed using a population-based database.
  • Cases done by general surgeons were compared with those done by pediatric surgeons.
  • RESULTS: Of 20,545 eligible hernia repairs, 50.3% were performed by pediatric surgeons and 49.7% were performed by general surgeons.
  • Pediatric surgeons operated on 62.4% of children younger than 2 years, 51.8% of children aged 26 years, and 37% of children older than 7 years.
  • Duration of operation, length of hospital stay, and incidence of early postoperative complications were similar among pediatric and general surgeons.
  • The rate of recurrent inguinal hernia was higher in the general surgeon group compared with pediatric surgeons (1.10% vs 0.45%, P < .001).
  • Among pediatric surgeons, the estimated risk of hernia recurrence was independent of surgical volume.
  • There was a significant inverse correlation between surgeon volume and recurrence risk among general surgeons, with the highest volume general surgeons achieving recurrence rates similar to pediatric surgeons.
  • CONCLUSIONS: Pediatric surgeons have a lower rate of recurrence after inguinal hernia repair in children.
  • General surgeons with high volumes have similar outcomes to pediatric surgeons.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868562.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M: Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg; 2010 Feb;45(2):387-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of the hedgehog signaling pathway in pediatric solid malignancies.
  • However, the correlation between the Hh signaling and tumorigenesis of pediatric malignancies has not been well documented.
  • The present study was undertaken to examine the expression of the Hh signaling pathway in various pediatric tumors to elucidate the role of Hh signaling in pediatric malignancies.
  • METHODS: Surgical specimens were obtained from 68 patients with pediatric malignancies (neuroblastoma, 25; rhabdomyosarcoma, 18; hepatic tumor, 12; and renal tumor, 13).
  • CONCLUSIONS: These findings suggest that the Shh-Ptch1-Gli1 signaling pathways are frequently activated in most pediatric malignant tumors.
  • The Hh signaling pathway may therefore play an important role in the differentiation and malignant potential of pediatric malignancies.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20152358.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


96. Kumar J, Seith A, Bakhshi S, Sharma R, Kumar A: Multifocal non-Hodgkin lymphoma in an infant with cardiac involvement: whole-body MR imaging. Pediatr Radiol; 2007 Mar;37(3):321-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal non-Hodgkin lymphoma in an infant with cardiac involvement: whole-body MR imaging.
  • Non-Hodgkin lymphoma (NHL) is rare in infancy, and we present a case of aggressive NHL of T-cell lineage in an infant with multifocal bone, cardiac, mediastinal nodal, paranasal sinus, calvarial, and soft-tissue deposits on presentation that were detected on whole-body MRI.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17262185.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


97. Gaiser T, Haedicke W, Becker MR: A rare pediatric case of a thymic cytotoxic and lymphoblastic T/NK cell lymphoma. Int J Clin Exp Pathol; 2010;3(4):437-42
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare pediatric case of a thymic cytotoxic and lymphoblastic T/NK cell lymphoma.
  • Attempts to establish a concise classification of lymphoblastic lymphomas (LBLs) have gained momentum in recent years, mainly due to the expanding possibilities of immunohistochemical and genetic characterization of different disease entities.
  • To further characterize and demonstrate the extended spectrum of LBL, we present an unusual pediatric case of LBL that could not be categorized into one of the subgroups and exhibited a benign course after surgical treatment and subsequent chemotherapy.
  • However, our case represents a rare pediatric lymphoma derived from a thymic precursor committed to T/NK-cell differentiation and a favourable outcome after chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Natural Killer T-Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1984 Nov 22;311(21):1373-5 [6593597.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1425-36 [18286525.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):539-54 [11962758.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):852-62 [12131152.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):175-84 [12876666.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1366-74 [14508398.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):167-73 [15023409.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):183-90 [2954631.001]
  • [Cites] Blood. 1989 Feb;73(2):381-90 [2783859.001]
  • [Cites] Blood. 1991 Jul 1;78(1):192-6 [1648975.001]
  • [Cites] Biotechniques. 1992 May;12(5):702, 704 [1381195.001]
  • [Cites] Immunol Today. 1992 Oct;13(10):392-5 [1418374.001]
  • [Cites] J Virol Methods. 1993 Oct;44(2-3):261-9 [8263120.001]
  • [Cites] J Exp Med. 1994 Aug 1;180(2):569-76 [7519241.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2592-603 [8640711.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2417-28 [9310493.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] Semin Immunol. 1999 Feb;11(1):39-46 [9952357.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1715-23 [15928199.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):485-92 [16087715.001]
  • [Cites] Ann Hematol. 2000 Nov;79(11):635-9 [11131924.001]
  • (PMID = 20490334.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2872750
  • [Keywords] NOTNLM ; T/NK cell lymphoma / lymphoblastic lymphomas / pediatric lymphoma
  •  go-up   go-down


98. Chan CM, Deave T, Greenhalgh T: Obesity in Hong Kong Chinese preschool children: where are all the nurses? J Pediatr Nurs; 2010 Aug;25(4):264-73
MedlinePlus Health Information. consumer health - Obesity in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Child Nutrition Disorders. Obesity. Pediatric Nursing / organization & administration

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Child Nutrition.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620807.001).
  • [ISSN] 1532-8449
  • [Journal-full-title] Journal of pediatric nursing
  • [ISO-abbreviation] J Pediatr Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH: The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia; 2009 Aug;23(8):1417-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • We explored the impact of mutations in the NOTCH1, FBW7 and PTEN genes on prognosis and downstream signaling in a well-defined cohort of 47 patients with pediatric T-cell acute lymphoblastic leukemia (T-ALL).
  • Our results suggest that (1) multiple factors should be considered with attempting to identify molecular-based prognostic factors for pediatric T-ALL, and (2) depending on the NOTCH1 signaling status, modifications in the types or dosing of standard chemotherapy drugs for T-ALL, or combinations of agents capable of targeting NOTCH1, AKT and/or mTOR with standard chemotherapy agents may be warranted.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3762-74 [18830414.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45031-40 [11564735.001]
  • [Cites] Genes Dev. 2002 Feb 1;16(3):295-300 [11825871.001]
  • [Cites] Immunity. 2002 Feb;16(2):231-43 [11869684.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):673-84 [12209127.001]
  • [Cites] EMBO Rep. 2002 Sep;3(9):840-5 [12223465.001]
  • [Cites] J Cell Physiol. 2003 Mar;194(3):237-55 [12548545.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5834-41 [12794108.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23196-203 [12682059.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6854-7 [15466172.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cell. 1991 Nov 15;67(4):687-99 [1657403.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):635-8 [9916679.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8530-7 [16166334.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1074-9 [16489059.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):451-7 [17255265.001]
  • [Cites] Cell Cycle. 2007 Jan 1;6(1):80-4 [17245125.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Development. 2000 Jul;127(14):3185-95 [10862754.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):197-206 [10882062.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • (PMID = 19340001.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076641-10; United States / NCI NIH HHS / CA / T32-CA009531; United States / NCI NIH HHS / CA / R01 CA076641; United States / NCI NIH HHS / CA / CA76641; United States / NCI NIH HHS / CA / T32 CA009531-22; United States / NCI NIH HHS / CA / T32 CA009531; United States / NCI NIH HHS / CA / T32 CA009531-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Neoplasm Proteins; 0 / Receptor, Notch1; 149348-15-2 / HES1 protein, human; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ NIHMS98506; NLM/ PMC2726275
  •  go-up   go-down


100. Sindhi R, Manavalan JS, Magill A, Suciu-Foca N, Zeevi A: Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28- T-suppressor cells. Hum Immunol; 2005 Mar;66(3):252-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28- T-suppressor cells.
  • Twelve pediatric liver (n = 7), liver-kidney (n = 1), and small bowel (n = 4) transplant recipients, median age 6.5 years (1-21), who received rabbit anti-human thymocyte globulin (rATG) and steroid-free tacrolimus/sirolimus, were screened for the presence of CD8+CD28- T suppressor cells.
  • CD8+CD28- T-suppressor cells were present in 4/4 children with no immunosuppression, and absent from three of four subjects with acute cellular rejection, all of whom experienced more than one acute cellular rejection episode.

  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784463.001).
  • [ISSN] 0198-8859
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 5R01AI49156-04; United States / NHLBI NIH HHS / HL / HL074732; United States / NCRR NIH HHS / RR / M01 RR00084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement